共 50 条
- [41] Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients With High-risk Endometrial Cancer After Staging Surgery: A Phase 2 StudyINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (05): : 1229 - 1236Kang, Ok-JuCho, Yoon-JungLim, Myong CheolLee, Yeon JeeSeo, Sang SooKang, SokbomPark, Sang-YoonKim, Young SeokNam, Joo-HyunPark, Jeong-Yeol
- [43] DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UPFROMTHE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMAJOURNAL OF UROLOGY, 2022, 207 (05) : E183 - E183Galsky, MatthewWitjes, Johannes AlfredGschwend, Jurgen E.Schenker, MichaelValderrama, Begona P.Tomita, YoshihikoBamias, AristotelisLebret, ThierryShariat, Shahrokh F.Park, Se HoonAgerbaek, MadsJha, GautamStenner, Frank StennerCollette, SandraUnsal-Kacmaz, KezibanNasroulah, FedericoZhang, JoshuaBajorin, Dean F.
- [44] First-line Treatment for locally advanced or metastatic Urothelial Carcinoma: A randomized, double-blind Phase-III-Multicenter Study of adjuvant Nivolumab Therapy versus Placebo in Patients with invasive High-Risk Urothelial CarcinomaAKTUELLE UROLOGIE, 2018, 49 (04) : 308 - 309Rexer, H.Ohlmann, C. -H.Gschwend, J.
- [45] Preliminary results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post surgery recurrence.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wu, ZhengWang, ZhengZhang, LeiSong, XiaojingDu, XilinTan, Kai
- [46] Gene expression as a predictive marker of outcome for high risk transitional-cell carcinoma (TCC) of the bladder in patients (PTS) randomized to adjuvant chemotherapy with cisplatin-gemcitabine (PG) or observation (OBS) after radical cystectomyANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83Pollera, C. F.Pessina, G.Nelli, F.Felici, A.Sperduti, IRuggeri, E. M.Mottolese, M.Gallucci, M.Cognetti, F.
- [47] Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resectionJOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 571 - 571Chen, YiwenShen, YanZhang, MinWu, JianGao, ShunliangQue, RishengYu, JunTang, XiaofengBai, XueliLiang, Tingbo
- [48] Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery-A single-arm, multicenter, phase II clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16120 - E16120Wu, ZhengWang, ZhengZhang, LeiSong, XiaojingDu, XilinTan, Kai
- [49] Gene expression as a predictive marker of outcome for high-risk transitional-cell carcinoma (TCC) of the bladder in patients (pts) randomized to adjuvant chemotherapy with cisplatin-gemcitabine (PG) or observation (OBS) after radical cystectomyJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Pollera, C. F.Pessina, G.Nelli, F.Felici, A.Moscetti, L.Ruggeri, E.Mottolese, M.Gallucci, M.Sperduti, I.Cognetti, F.
- [50] HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: A single-centre, non-randomised, open clinical studyANNALS OF ONCOLOGY, 2023, 34 : S597 - S597Zhang, T.Wang, L.Zhao, Y.Pan, Q.Mao, A.Zhu, W.Zhang, N.Zhang, Y.